Experienced managers with an entrepreneurial mindset

After graduating from HEC in 1989 and the financial track of INSEAD in 1996, he immediately joined Deutsche Bank’s Healthcare Group in Frankfurt and then Baltimore and New York.

While on assignment as an expatriate for Deutsche Bank, he managed to pioneer and supercharge the development of the merging Deutsche Bank cross-border franchise alongside the transatlantic trajectory, providing a maximizing exposure to the globalization of healthcare and a quantum-leap in both Client and knowledge databases, since he was bringing a totally different jurisdictional and cultural background to his US Clients.

He then took over the M&A Group at Boehringer Ingelheim in 2003, a career inflection point with regards to his life- science knowledge, because of the intensive interaction with scientists and biologists, epidemiologists… Corporate M&A is a different discipline than investment banking M&A, which enables him to decipher how M&A is perceived within large Corporates and to focus on further fundamental aspects such as remaining and restructuring costs and socio-political repercussions such as pension, employment continuation guarantees and phased social plans.

He also refined his sensitivity to operational aspects of all ancillary agreements to be entered concurrently with the principal Sale and Purchase Agreement and gained first-ranking exposure to strategic and business development/portfolio management aspects, such as globalization of footprint, bio-generics threats, leverage of manufacturing and sales-force capacities.

He then went on to lead Cowen’s European Healthcare Investment Banking in London from 2007, rebuilding the European franchise, and developing its US and Global Client network, reengaging them at the Top Level into an intense M&A-dialogue with Top Clients, as the driving force originating numerous cross-border M&A transactions especially in the vaccine, drug delivery technology, CRO, dermatology and dermatology and oncology biotech.

From 2008 to 2010, he was Senior M&A Adviser at Bryan, Garnier in Paris, where he led-managed the execution of a Capital Markets and M&A transactions in the ophthalmology sector (IPO of Novagali in 2010), oncology biotech and immuno-therapeutics ( Share Capital Increase of Transgene in 2010), diagnostics in oncology (Exonhit’s IPO in 2009) and in CNS (IPO of Integragen in 2010 ) and M&A transactions (divestiture of Institut Mérieux’s Vaccine Business Shantha Biotechnics in 2009) as well as acquisition by Biomérieux of AES-Chemunex in 2010.

During his 13 years’ tenure at Michel Dyens, he elevated his expertise in M&A and partnerships transactions in the Specialty Pharma, Vaccines, Diagnostics, Medtech and especially Medical Aesthetics spaces, Physician-Dispensed Skincare and Healthcare services. He also focused on situations involving the therapy and patient-centric management of age-related chronic, degenerative diseases and the area of regenerative and reconstructive medicine as well as medical spas offering facial and body remodeling services (Transactions).

Jean-Yves has been a keynote speaker on megatrends, prospectives and M&A valuations at the World Economic Tribunes of IMCAS for 10 years and was recently invited to intervene at other prestigious and influential events such as SOFCEP in France, the Aesthetic Innovation Summit in the US or online at the Global Virtual Aesthetic Summit.

Prior to joining Windome, he held senior leadership positions at leading real estate and investment development firms including Inovim Développement, OGIC, and Société Générale Promotion (Sogeprom), where he successfully led complex operations across commercial, industrial, residential, and managed-residence asset classes generating cumulative transactional value in excess of € 420M. His work has spanned business development, strategic partnerships, and astute skills in large-scale project management with a strong focus on sustainability, smart-city innovation, and low-carbon construction as well as a proven track-record and expertise in health-related real-estate transactions including financing and restructuring of clinics and a ramified network of relationships across the French and European PE, VC and Family Office as well as UHNWI ecosystem.

Sébastien holds an Executive Master in Sustainable Real Estate and Building – Energy and Digital Transitions from École des Ponts ParisTech, a Master’s in Real Estate Management (MMI) from ESSEC Business School, and a Master’s in Real Estate and Construction Law from Université Paris II Panthéon-Assas.

Fluent in English, French, and Spanish, Sébastien brings to Windome Banking Partners a unique combination of legal, financial, and technical expertise, flexibility and adaptability together with a dynamic enthusiasm for tailor-made deal-making matching expectations of buy- and sell-side, forward-looking vision centered on pioneering innovation, digital transformation, agility and sustainable value creation via an impeccable dedication to clients ‘ servicing needs.